BR9607565A - Derivados de hidroxilamina úteis para produção de protetores moleculares e sua preparação - Google Patents

Derivados de hidroxilamina úteis para produção de protetores moleculares e sua preparação

Info

Publication number
BR9607565A
BR9607565A BR9607565A BR9607565A BR9607565A BR 9607565 A BR9607565 A BR 9607565A BR 9607565 A BR9607565 A BR 9607565A BR 9607565 A BR9607565 A BR 9607565A BR 9607565 A BR9607565 A BR 9607565A
Authority
BR
Brazil
Prior art keywords
cell
molecular
hydroxylamine derivative
protectors
preparation
Prior art date
Application number
BR9607565A
Other languages
English (en)
Other versions
BR9607565B1 (pt
Inventor
Laszlo Vigh
Peter Literatinagy
Jeno Szilbereky
Laszlo Urogdi
Andrea Jednakovits
Laszlo Jaszlits
Ede Marvanyos
Katalin Biro
Mihaly Barabas
Erzsebet Hegedus
Laszlo Koranyi
Maria Kurthy
Gabor Balogh
Ibolya Horvath
Zsolt Torok
Eva Udvardy
Gyorgy Dorman
Denes Medzaihradszky
Bea Mezes
Eszter Kovacs
Erno Duda
Beatrix Farkas
Attila Glatz
Original Assignee
Biorex Kutato Fejlesztoe Kft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27270113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9607565(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biorex Kutato Fejlesztoe Kft filed Critical Biorex Kutato Fejlesztoe Kft
Publication of BR9607565A publication Critical patent/BR9607565A/pt
Publication of BR9607565B1 publication Critical patent/BR9607565B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/02—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/12—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines
    • C07C259/18—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines having carbon atoms of hydroxamidine groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/64—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups singly-bound to oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/18—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI9607565-1A 1995-11-02 1996-11-01 derivados de hidroxilamina úteis para produção de protetores moleculares e composições que os contêm. BR9607565B1 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
HU9503141A HU222994B1 (hu) 1995-11-02 1995-11-02 Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
HUP9503141 1995-11-02
HU9603919 1996-02-09
HUP9503141/3919 1996-02-09
HUP9503141/29820 1996-10-04
HU9629820 1996-10-04
PCT/HU1996/000064 WO1997016439A1 (en) 1995-11-02 1996-11-01 Hydroxylamine derivatives useful for enhancing the molecular chaperon production and the preparation thereof

Publications (2)

Publication Number Publication Date
BR9607565A true BR9607565A (pt) 1999-07-20
BR9607565B1 BR9607565B1 (pt) 2011-08-23

Family

ID=27270113

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9607565-1A BR9607565B1 (pt) 1995-11-02 1996-11-01 derivados de hidroxilamina úteis para produção de protetores moleculares e composições que os contêm.

Country Status (31)

Country Link
US (4) US6653326B1 (pt)
EP (1) EP0801649B1 (pt)
JP (2) JP4531865B2 (pt)
KR (1) KR19980700976A (pt)
CN (1) CN1152871C (pt)
AT (1) ATE221880T1 (pt)
AU (1) AU720195B2 (pt)
BG (1) BG63944B1 (pt)
BR (1) BR9607565B1 (pt)
CA (1) CA2209167C (pt)
CZ (1) CZ295562B6 (pt)
DE (1) DE69622840T2 (pt)
DK (1) DK0801649T3 (pt)
EE (1) EE04239B1 (pt)
ES (1) ES2176502T3 (pt)
HR (1) HRP960508B1 (pt)
HU (1) HU222994B1 (pt)
IL (1) IL121126A (pt)
MX (1) MX9704988A (pt)
NO (1) NO321140B1 (pt)
NZ (1) NZ320523A (pt)
PL (1) PL195634B1 (pt)
PT (1) PT801649E (pt)
RS (1) RS49981B (pt)
RU (1) RU2206320C2 (pt)
SI (1) SI0801649T1 (pt)
SK (1) SK284823B6 (pt)
TR (1) TR199700574T1 (pt)
UA (1) UA61050C2 (pt)
WO (1) WO1997016439A1 (pt)
ZA (1) ZA969249B (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT78139A (hu) * 1995-12-22 2000-11-28 BIOREX Kutató és Fejlesztő Rt. Készítmény, különösen a bőr öregedési folyamatainak mérséklésére
UA64716C2 (en) * 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells
AU5296799A (en) * 1998-08-03 2000-02-28 N-Gene Kutato Kft. Pharmaceutical compositions against autoimmune diseases
HU226617B1 (en) * 1998-12-14 2009-04-28 Cytrx Corp Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, and pharmaceutical composition containing the compound as active ingredient
HUP9900475D0 (en) * 1999-02-26 1999-04-28 Biorex Kutato Fejlesztoe Kft O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component
FR2792832B1 (fr) * 1999-04-28 2002-05-10 Codif Internat Sa Procede de protection de la peau pour la prevenir de son vieillissement cellulaire
HUP0001583A2 (hu) * 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké
WO2003000861A2 (en) * 2001-06-22 2003-01-03 The Regents Of The University Of California Eukaryotic genes involved in adult lifespan regulation
HUP0105205A2 (hu) * 2001-11-29 2003-08-28 BIOREX Kutató és Fejlesztő Rt. Metformint és egy hidroxilaminszármazékot tartalmazó, gyógyászati készítmény
KR20040089102A (ko) * 2002-01-11 2004-10-20 비오렉스 쿠타토 에쉬 훼레스테 에르테 카르복사미딘 유도체 및 혈관 질환의 치료에서의 이들 용도
AU2004225472B2 (en) * 2003-03-27 2011-02-10 Children's Hospital Medical Center A method and kit for detecting the early onset of renal tubular cell injury
HUP0303584A3 (en) * 2003-10-30 2009-12-28 Cytrx Corp Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
JP4790704B2 (ja) * 2004-04-12 2011-10-12 トレント・ファーマシューティカルズ・リミテッド Ｈｓｐ７０誘発因子としての２−プロペン−１−オン
JP4787159B2 (ja) * 2004-07-07 2011-10-05 ハウスウェルネスフーズ株式会社 抗ストレス剤
FR2880022B1 (fr) * 2004-12-24 2007-08-24 Mayoly Spindler Soc Par Action Nouveaux derives de la n-hydroxy-n'-phenyluree et de la n-hydroxy-n'-phenylthiouree et leur utilisation comme inhibiteurs de la synthese de la melanine
US20080227813A1 (en) * 2006-09-26 2008-09-18 Jack Raymond Barber Pharmaceutical compositions and methods for treating diseases associated with neurodegeneration
WO2008070010A2 (en) * 2006-12-01 2008-06-12 Cytrx Corporation Hydroxylamine derivatives for the treatment of stroke
TW200901958A (en) * 2007-05-04 2009-01-16 Cytrx Corp Diabetic wound healing
KR20100027241A (ko) * 2007-06-29 2010-03-10 토렌트 파마슈티칼스 리미티드 Ｈｓｐ 인듀서로서 신규의 치환된 피페리돈
WO2009155936A1 (en) * 2008-06-26 2009-12-30 Orphazyme Aps Use of hsp70 as a regulator of enzymatic activity
KR101645937B1 (ko) * 2008-11-11 2016-08-08 (주)아모레퍼시픽 육음외사에 의한 피부 변화를 정량하는 방법 및 이를 이용한 피부 개선 물질의 스크리닝 방법
JP2010150243A (ja) * 2008-11-18 2010-07-08 Santen Pharmaceut Co Ltd ピリジン−３−カルバルデヒドｏ−（ピペリジン−１−イル−プロピル）−オキシム誘導体を有効成分として含有する網脈絡膜変性疾患の治療剤
US20110123473A1 (en) * 2009-11-26 2011-05-26 Basf Se Use of highly-branched polycarbonates in cosmetic and dermatological formulations
AU2011335545A1 (en) 2010-11-30 2013-06-13 Orphazyme Aps Methods for increasing intracellular activity of Hsp70
KR101275264B1 (ko) 2011-08-24 2013-06-17 포항공과대학교 산학협력단 샤프로닌 단백질의 조절 물질 탐색 방법
HUP1100534A2 (en) 2011-09-26 2013-04-29 Balazs Dr Hazay Pharmaceutical composition for the treatment of muscle atrophy
HUP1100535A2 (en) 2011-09-26 2013-04-29 Bracelia Invest Ltd Pharmaceutical composition for enhancement of stem cell treatment
RU2495928C2 (ru) 2012-01-30 2013-10-20 Сергей Юрьевич Лешков Средство для стимуляции синтеза белков теплового шока hsp 70 в клетках человека и животных; косметическое средство для стимуляции репаративных процессов; косметическое средство для снижения побочных эффектов агрессивных косметологических процедур; биологически активная добавка; пищевой продукт; способ снижения побочных эффектов агрессивных косметологических процедур
AU2015317447B2 (en) 2014-09-15 2021-02-25 Zevra Denmark A/S Arimoclomol formulation
US10898476B2 (en) 2016-04-13 2021-01-26 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
KR102254140B1 (ko) * 2016-04-29 2021-05-24 오르파짐 에이/에스 글루코세레브로시다제 연관 장애를 치료하기 위한 아리모클로몰
BR112019024667A2 (pt) 2017-05-24 2020-06-16 Orphazyme A/S Uso de um agente bioativo, e, de uma composição
CN108314630B (zh) * 2018-02-08 2020-11-06 广西民族大学 一种肟醚类衍生物及其制备方法与应用
EP3803406A1 (en) 2018-05-28 2021-04-14 Orphazyme A/S Hsp70 protein levels in pbmc samples as biomarker for disease
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
CN110048418B (zh) * 2019-05-08 2023-03-24 辽宁工程技术大学 一种基于细胞-组织算法的微电网经济调度方法及装置
WO2021260120A1 (en) 2020-06-24 2021-12-30 Orphazyme A/S Arimoclomol for treating gaucher disease
CN112094878A (zh) * 2020-08-18 2020-12-18 周银根 一种二步酶提取香菇多糖的方法、香菇多糖提取物及其应用
IL303026A (en) 2020-11-19 2023-07-01 Zevra Denmark As Processes for preparing arimoclomol citrate and its intermediates
WO2022136640A1 (en) 2020-12-24 2022-06-30 Orphazyme A/S Arimoclomol for the treatment of niemann pick disease, type c, in patients with er type missense mutations
CA3237171A1 (en) * 2021-09-28 2023-04-06 Zevra Denmark A/S Dioxazines and their use in treatment of gba-related diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU177578B (en) * 1976-08-27 1981-11-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing new 0-/3-amino-2-hydroxy-propyl/-amidoxime derivatives
DE2651083A1 (de) * 1976-11-09 1978-05-18 Hoechst Ag Neue o-alkylierte hydroxylamine, verfahren zu ihrer herstellung und ihre verwendung
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
HUT54347A (en) * 1989-01-10 1991-02-28 Chinoin Gyogyszer Es Vegyeszet Improved process for producing amidoximes
US5334600A (en) * 1991-07-30 1994-08-02 Ciba-Geigy Corporation Isoquinolyl substituted hydroxylamine derivatives
HU216830B (hu) 1992-07-21 1999-09-28 BIOREX Kutató és Fejlesztő Rt., N-[2-Hidroxi-3-amino-propoxi]-amidok és -imidátok, valamint dioxazinok, eljárás ezek előállítására, és a vegyületeket tartalmazó gyógyszerkészítmények
ES2123252T3 (es) * 1994-05-06 1999-01-01 Biorex Kutato Fejlesztoe Kft Nuevos derivados de acido hidroximico, composiciones farmaceuticas que los contienen y procedimiento para su preparacion.
HU9502843D0 (en) * 1995-09-29 1995-11-28 Livigene Ltd Pharmaceutical composition

Also Published As

Publication number Publication date
BG101713A (en) 1998-03-31
SI0801649T1 (en) 2002-12-31
NO973059L (no) 1997-09-02
EE04239B1 (et) 2004-02-16
US20040067940A1 (en) 2004-04-08
US20040019103A1 (en) 2004-01-29
DK0801649T3 (da) 2002-12-02
PT801649E (pt) 2002-12-31
CA2209167C (en) 2009-05-19
RU2206320C2 (ru) 2003-06-20
BG63944B1 (bg) 2003-07-31
NO321140B1 (no) 2006-03-27
EE9700146A (et) 1997-12-15
RS49981B (sr) 2008-09-29
US7148239B2 (en) 2006-12-12
BR9607565B1 (pt) 2011-08-23
DE69622840T2 (de) 2003-04-30
WO1997016439A1 (en) 1997-05-09
HU9503141D0 (en) 1995-12-28
CN1152871C (zh) 2004-06-09
ATE221880T1 (de) 2002-08-15
NZ320523A (en) 2001-05-25
HRP960508A2 (en) 1998-06-30
HRP960508B1 (en) 2004-10-31
SK88197A3 (en) 1998-04-08
TR199700574T1 (xx) 1999-08-23
CZ207297A3 (cs) 1998-03-18
EP0801649A2 (en) 1997-10-22
CA2209167A1 (en) 1997-05-09
ZA969249B (en) 1998-03-02
IL121126A (en) 2002-07-25
KR19980700976A (pt) 1998-04-30
HU222994B1 (hu) 2004-01-28
US6653326B1 (en) 2003-11-25
MX9704988A (es) 1998-07-31
JPH10512590A (ja) 1998-12-02
SK284823B6 (sk) 2005-12-01
PL322015A1 (en) 1998-01-05
AU7326396A (en) 1997-05-22
PL195634B1 (pl) 2007-10-31
IL121126A0 (en) 1997-11-20
YU58796A (sh) 1999-09-27
NO973059D0 (no) 1997-07-01
EP0801649B1 (en) 2002-08-07
UA61050C2 (en) 2003-11-17
JP4531865B2 (ja) 2010-08-25
DE69622840D1 (de) 2002-09-12
HUT76659A (en) 1997-10-28
US20100267711A1 (en) 2010-10-21
US7745465B2 (en) 2010-06-29
JP2009108048A (ja) 2009-05-21
ES2176502T3 (es) 2002-12-01
AU720195B2 (en) 2000-05-25
CZ295562B6 (cs) 2005-08-17
CN1177351A (zh) 1998-03-25

Similar Documents

Publication Publication Date Title
BR9607565A (pt) Derivados de hidroxilamina úteis para produção de protetores moleculares e sua preparação
GEP20012580B (en) Substituted 4-Hydroxy-Phenylalcanoic Acid Derivatives With Agonist Activity to PPAR-Gamma, Methods for Their Production, Pharmaceutical Conposition and Methods for Treatment
UA44254C2 (uk) Похідні 4-(заміщеного феніламіно)хіназоліну, спосіб їх одержання, спосіб лікування і фармацевтична композиція
ES2161291T3 (es) N-(indol-2-carbonil)amidas y derivados como inhibidores de la glucogeno fosforilasa.
ATE219363T1 (de) Lösliche prodrugs von paclitaxel
ATE212351T1 (de) Androsten-derivate
HUP9602498A2 (hu) Antimikrobiális hatású gyógyászati készítmények
BRPI0407652A (pt) método para acentuar a eficácia de um agente ativo, composição e método para produzir a composição
ES2108129T3 (es) Nuevos derivados de pirazina, su preparacion y empleo.
DK284386D0 (da) Farmaceutisk praeparat mod hudlidelser
NO982863L (no) Nye forbindelser med analgetisk effekt
FI861329A (fi) Anvaendning av 4-(isoxazolyl)-tiazol-2-oxaminsyraderivat.
ATE206105T1 (de) Alkykendiamin di- oder tri-essigsäurederivate, verfahren zu ihrer herstellung und ihre verwendung in kosmetischen zusammensetzungen
ES8200871A1 (es) Procedimiento para la obtencion de derivados de 2-amino-3,4-dihidropiridina
ATE275953T1 (de) 2,3 diaryl-1-benzopyrame zur behandlung von dermatitis
SE9802207D0 (sv) Novel compounds
AR009470A1 (es) COMPOSICIoN FARMACÉUTICA QUE CONTIENE CEPAS BACTERIANAS Y UTILES EN EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS CON O CAUSADAS POR ALTERACIONES EN EL METABOLISMO DE LOS ÁCIDOS BILIARES, Y USO DE LAS MISMAS.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO POR NAO ATENDER AO DISPOSTO NOS ARTIGOS 24 E 25 DA LPI 9.279/96

B12B Appeal against refusal [chapter 12.2 patent gazette]
B25A Requested transfer of rights approved

Owner name: CYTRX CORPORATION (US)

Free format text: TRANSFERIDO DE: BIOREX KUTATO ES FEJLESZTO RT.

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/08/2011, OBSERVADAS AS CONDICOES LEGAIS.

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI-52400.061188/2013 ORIGEM: JUIZO DA 013A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0132258-48.2013.4.02.5101 ACAO DE NULIDADE DAS PATENTES SUBMETIDAS AO MAILBOX (ART. 229, PARAGRAFO UNICO DA LPI); ALTERNATIVAMENTE, A DECRETACAO DA NULIDADE PARCIAL PARA CORRECAO DO PRAZO DE VIGENCIA; SUBSIDIARIAMENTE, CASO SE ENTENDA NAO SER O CASO DE NULIDADE, A CORRECAO DO ATO ADMINISTRATIVO PARA ADEQUACAO DA VIGENCIA DAS PATENTES. AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU: CEPHALON, INC, CIBA SPECIALTY CHEMICALS HOLDING INC. - CIBA SPEZIALITAETENCHEMIE HOLDING AG - CIBA SPECIALITES CHIMIQUES HOLDING SA, CYTRX CORPORATION.

B21B Extinction acc. art. 78, item ii - on waiver by the patentee, without prejudice to the rights of third parties

Free format text: SOLICITADA ATRAVES DA PETICAO 860130003424, DE 30/09/2013